Drug interactions
Dosulepin + Ethinyl estradiol-drospirenone
Severity: Minor
Dosulepin and Ethinyl estradiol-drospirenone: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Estrogen-containing contraceptives may raise tricyclic antidepressant exposure, and a few reports suggest more anticholinergic, sedative or cardiovascular adverse effects. The effect is variable and usually modest. Dosulepin-specific data are scarce.
What this interaction means in plain words
Dosulepin and Ethinyl estradiol-drospirenone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Dosulepin belongs to Central Nervous System; Ethinyl estradiol-drospirenone belongs to Endocrine.
Why it happens
Ethinyl estradiol may inhibit oxidative metabolism of tricyclic antidepressants, though the mechanism is not firmly established.
What to do
Monitor for increased tricyclic adverse effects such as sedation, dry mouth and tachycardia after starting the contraceptive. Reduce the dosulepin dose if these effects appear.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dosulepin and Ethinyl estradiol-drospirenone, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ethinyl estradiol-drospirenone
- Ethinyl estradiol-drospirenone + Fezolinetant Contraindicated
- Ethinyl estradiol-drospirenone + Ombitasvir / paritaprevir / ritonavir Contraindicated
- Ethinyl estradiol-drospirenone + Ombitasvir / paritaprevir / ritonavir and dasabuvir Contraindicated
- Ethinyl estradiol-drospirenone + Tranexamic acid Contraindicated
- Aminocaproic acid + Ethinyl estradiol-drospirenone Major
- Amobarbital + Ethinyl estradiol-drospirenone Major
Other interactions of Dosulepin
- Dosulepin + Isocarboxazid Contraindicated
- Dosulepin + Phenelzine Contraindicated
- Dosulepin + Thioridazine Contraindicated
- Dosulepin + Tranylcypromine Contraindicated
- Amitriptyline + Dosulepin Major
- Buprenorphine + Dosulepin Major
Frequently asked questions
Can I take Dosulepin with Ethinyl estradiol-drospirenone?
MediHelp rates the interaction as minor. Dosulepin and Ethinyl estradiol-drospirenone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Estrogen-containing contraceptives may raise tricyclic antidepressant exposure, and a few reports suggest more anticholinergic, sedative or cardiovascular adverse effects. The effect is variable and usually modest. Dosulepin-specific data are scarce.
How serious is the interaction between Dosulepin and Ethinyl estradiol-drospirenone?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for increased tricyclic adverse effects such as sedation, dry mouth and tachycardia after starting the contraceptive. Reduce the dosulepin dose if these effects appear.
What other medicines interact with Ethinyl estradiol-drospirenone?
MediHelp also lists interactions of Ethinyl estradiol-drospirenone with, for example, Fezolinetant, Ombitasvir / paritaprevir / ritonavir, Ombitasvir / paritaprevir / ritonavir and dasabuvir. The full list is on the Ethinyl estradiol-drospirenone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
